Edition:
United Kingdom

Insmed Inc (INSM.OQ)

INSM.OQ on NASDAQ Stock Exchange Global Select Market

27.47USD
19 Jun 2018
Change (% chg)

-- (--)
Prev Close
$27.47
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
266,415
52-wk High
$33.94
52-wk Low
$11.49

Chart for

About

Insmed Incorporated is a biopharmaceutical company. The Company operates through development and commercialization of therapies for patients with rare diseases segment. Its lead product candidate is ARIKAYCE, or liposomal amikacin for inhalation (LAI), which is in late-stage development for adult patients with treatment... (more)

Overall

Beta: 1.20
Market Cap(Mil.): $2,392.91
Shares Outstanding(Mil.): 76.50
Dividend: --
Yield (%): --

Financials

  INSM.OQ Industry Sector
P/E (TTM): -- 84.11 32.75
EPS (TTM): -3.04 -- --
ROI: -92.57 1.56 14.38
ROE: -112.72 2.43 16.07

BRIEF-Insmed Announces FDA Acceptance For Filing Of NDA For Lung Disease Treatment

* INSMED ANNOUNCES FDA ACCEPTANCE FOR FILING OF NEW DRUG APPLICATION FOR ALIS IN NTM LUNG DISEASE CAUSED BY MAC

16 May 2018

BRIEF-Insmed Reports Q1 Loss Per Share $0.89

* INSMED REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

02 May 2018

BRIEF-Insmed Inc Submits NDA To FDA For ALIS

* INSMED SUBMITS NEW DRUG APPLICATION TO FDA FOR ALIS IN NTM LUNG DISEASE CAUSED BY MAC

29 Mar 2018

BRIEF-Insmed Reports Q4 Loss Per Share $0.85

* INSMED REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

23 Feb 2018

BRIEF-Insmed Prices Public Offering Of $400 Mln Principal Amount Of Its Convertible Senior Notes

* INSMED ANNOUNCES PRICING OF PUBLIC OFFERING OF CONVERTIBLE SENIOR NOTES

24 Jan 2018

BRIEF-Insmed Announces Proposed Public Offering Of Convertible Senior Notes

* INSMED ANNOUNCES PROPOSED PUBLIC OFFERING OF CONVERTIBLE SENIOR NOTES

22 Jan 2018

Competitors

Earnings vs. Estimates